Last reviewed · How we verify
indomethacin suppositories
At a glance
| Generic name | indomethacin suppositories |
|---|---|
| Sponsor | Assiut University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prophylactic PS Placement to Prevent Pancreatitis After Endoscopic Transpapillary GPC for Cholelithiasis With Concomitant Choledocholithiasis (NA)
- Study Comparing Transobturator Cystocele vs. Anterior Vaginal RepairS (NA)
- Indian National Study to Assess Incidence and Severity of Post-ERCP Pancreatitis After Following SOP
- Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis (PHASE4)
- Aggressive Intravenous Hydration With or Without Indometacin to Prevent Pancreatitis After Pancreatic Extracorporeal Shock Wave Lithotripsy (NA)
- Prophylaxis of Post-ERCP Acute Pancreatitis (PHASE3)
- Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial) (PHASE4)
- Efficacy of Mepilex Lite Dressings in Treating Anal Pain (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- indomethacin suppositories CI brief — competitive landscape report
- indomethacin suppositories updates RSS · CI watch RSS
- Assiut University portfolio CI